• Pediatric Infection and Vaccine
• /
• 제15권2호
• /
• pp.108-114
• /
• 2008

Japanese encephalitis is the leading cause of viral encephalitis in Asia, where it accounts for up to 50,000 cases. Approximately 20% of affected patients die, and 30-50% of survivors have significant neurological sequelae. Inactivated mouse-brain derived Japanese encephalitis vaccines has been effectively implemented to control the disease effectively in Korea and several other Asian countries. However, the vaccine is expensive and difficult to produce, requires multiple doses, and has been associated with hypersensitivity reactions and rare adverse neurologicale events. The live-attenuated SA14-14-2 vaccine derived from primary hamster kidney (PHK) cells was developed in China and has been used there since 1988. Outside China, it has been licensed and used in Korea and several other Asian countries. This vaccine is effective and inexpensive. However, the lack of precedence for using a PHK cell substrate in a live-attenuated vaccine is a special issue of concern. The WHO working group has recommended additional safety studies in selected high-risk groups, as well as ongoing post-marketing studies to ensure long-term safety. Recently, a new inactivated vaccine and live-attenuated chimeric vaccine have been developed from vero cells. With this background, this article summarized the current status of Japanese encephalitis vaccination worldwide and in Korea.

• 한국동물위생학회지
• /
• 제46권3호
• /
• pp.193-202
• /
• 2023

Porcine epidemic diarrhea is an infectious intestinal disease caused by the porcine epidemic diarrhea virus (PEDV). Especially, when suckling piglets are infected, the mortality rate is close to 100%. PEDV is classified into G1 and G2 types based on genetic differences. The G2 type PEDV outbreak in the United States in 2013 was highly pathogenic and contagious, and it has spread worldwide and caused continuous economic losses. Most commercial vaccines used are G1 type vaccines, and existing vaccines do not fully protect piglets due to genetic differences. In this study, we evaluated the safety of the newly developed G2 type attenuated HSGP vaccine strain by inoculating it into piglets and testing whether the vaccine virus spreads to the non-vaccinated, negative pigs and whether the vaccine reverts to its virulence during serial passage experiments. Each experiment lasted for 7 days for each passage, and fecal viral titers, clinical symptoms, and weight gain were measured daily. After the experiment, necropsy was performed to measure intestinal virus titer and pathological evaluation. As a result of the first passage, no transmission of the vaccine virus to negative pigs co-housed with vaccinated pigs was observed. In addition, after four consecutive passage experiments, the clinical symptoms and small intestine lesions were gradually alleviated, and no virus was detected in the feces in the fourth passage experiment. Therefore, it was concluded that the vaccine was safe without virulence reversion in accordance with the guidelines of the current licensing authority. However, further studies are needed on the genetic changes and biological characteristics of the mutant virus that occur during successive passages of the attenuated vaccine since the replication and clinical symptoms of the virus increased until the third passage during successive passages of the vaccine virus. Based on this study, it was concluded that virulence reversion and safety evaluation of attenuated vaccines through serial passage in target animals can be useful to evaluate the safety of attenuated viruses.

• IMMUNE NETWORK
• /
• 제2권1호
• /
• pp.1-5
• /
• 2002

Estimated number of adults and children newly infected with HIV-1 during 2001 alone is 5 million in total. An effective vaccine, in addition to education & public health approaches, has been believed to be the best option to stop the HIV-1 transmission, especially for developing countries. Among AIDS vaccine candidates, DNA vaccine is relatively safe and, in a certain extent, mimics some attributes of live attenuated vaccine, with regard to in vivo gene expression & the type of immunity induced. We recently demonstrated that DNA vaccines expressing SIVmac239 structural and regulatory genes, augmented with coadministration of IL-12 mutant induced the strongest T cell responses, resulting in low to undetectable setpoint viral loads, stable $CD4^+$ T cell counts, and no evidence of clinical diseases or mortality by day 420 after challenge. This finding is the second demonstration, following the protective result of live attenuated SIV vaccine in SIVmac-rhesus monkey model, which was known to have safety problem. So, our DNA vaccines could give a significant impact on HIV-1 epidemic by slowing or stopping the spread of HIV-1, leading to eventual eradication of HIV-1 and AIDS in the population.

• KSBB Journal
• /
• 제25권6호
• /
• pp.497-506
• /
• 2010

Vaccine is a protective clinical measure capable of persuading immune system against infectious agents. Vaccine can be categorized as live attenuated and inactivated. Live attenuated vaccines activate immunity similar to natural infection by replicating living organisms whereas inactivated vaccines are either whole cell vaccines, eliciting immune response by killed organisms,or subunit vaccines, stimulating immunity by non-replicating sub cellular parts. The components of vaccine play a critical role in deciding the immune response mediated by the vaccine. The innate immune responds against the antigen component. Adjuvants represent an importantcomponent of vaccine for enhancing the immunogenicity of the antigens. Subunit vaccines with isolated fractions of killed and recombinant antigens are mostly co-administered with adjuvants. The delivery system of the vaccine is another essential component to ensurethat vaccine is delivered to the right target with right dosage form. Furthermore, vaccine delivery system ensures that the desired immune response is achieved by manipulating the optimal interaction of vaccine and adjuvantwith the immune cell. The aforementioned components along with routes of administration of vaccine are the key elements of a successful vaccination procedure. Vaccines can be administered either orally or by parenteral routes. Many groups had made remarkable efforts for the development of new vaccine and delivery system. The emergence of new vaccine delivery system may lead to pursue the immunization goals with better clinical practices.

• 대한수의학회지
• /
• 제58권3호
• /
• pp.137-141
• /
• 2018

The efficacy of the CA-2-MP120 vaccine, a cell culture-attenuated strain of virulent porcine reproductive and respiratory syndrome virus (PRRSV), was assessed in pigs. Despite the persistence of viremia in all vaccinated animals during the immunization period, the virus was not detected in vaccinated pigs following challenge. Furthermore, no pigs in the vaccinated group shed PRRSV nasally, orally or rectally throughout the experiment. Moreover, histopathological lung and lymph node lesions in the immunized group were much milder than those in the unimmunized and challenged group. These results indicated that CA-2-MP120 can provide effective protection against virulent wild-type PRRSV-2.

• 대한수의학회지
• /
• 제39권4호
• /
• pp.778-785
• /
• 1999

To detect CDV RNA in clinical samples and differentiate prevailing CDV virulent strains affecting susceptible animals from attenuated vaccine strains, we performed RT-PCR, RFLP, and sequencing. CDV specific primers were generated from the middle part of nucleocapsid gene. The expected size of PCR products, 519 bp, was observed in tissues of Jindo dog, poodle dog, badger, fourteen of nineteen blood samples as well as 5 vaccine strains including domestic and imported products. The PCR products obtained from tissues and PBMCs of infected animals were digested to 317- and 202-bp fragments by Bam HI, but the products obtained from four of five vaccine strains and Lederle strain were not digesed by Bam HI. Only one vaccine strain of which the PCR products were digested by Bam HI was confirmed as imported vaccine, modified Synider Hill strain. Based on seqencing data obtained from the 519-bp products, it was confirmed that Bam HI restriction site tends to be conserved in field isolates compared to the commercially available attenuated vaccine strains. Partial nucleotide sequences of CDV NP gene obtained from tissues of Jindo dog, poodle and badger shared 100% homology each other, whereas the nucleotide sequences showed 96.3, 96.5, 93.6 and 93.4% homology with Yanaka (virulent), Han95 (virulent), Lederle (attenuated) and Onderstepoort (attenuated) strain, respectively.

• 대한수의학회지
• /
• 제2권1호
• /
• pp.27-36
• /
• 1962

필자(筆者)는 한국(韓國)에 특(特)히 많이 유행(流行)하고 있는 가계(家鷄)의 유행병(流行病)인 Newcastle discase에 착안(着眼)하였다. 예방방법(豫防方法)으로서 종래(從來) 사용(使用)된 Forinalin-inactivated vaccine은 수산화(水酸化) "알미늄 젤"을 부가(賦加)하므로서 근육내주사방법(筋肉內注射方法)으로 사용(使用)할수 있게되어 사용방법(使用方法)이 비교적(比較的) 편리(便利)하게 되었으나 그 면역효과(免疫效果)에 대(對)하여서는 아직 이론(異論)이 있으므로 Hitcher등(等)이 제창(提唱)한 Attenuated Vaccine에 대(對)하여 더 흥미(興味)를 가지게 되었다. 특(特)히 이와같은 생독(生毒) Vaccine은 닭의 age에 차별(差別)없이 독력(毒力)이 거의 없을뿐만 아니라 경비적(經鼻的)으로 대단(大端)히 간이(簡易)한 방법(方法)으로도 투여(投與)할수 있고 고도(高度)의 면역(免疫)을 장기간(長期間) 부여(賦與)할수 있는 점(點)을 들어 기(其) 실용성(實用性)을 주목(注目)하게 되었다. 그러나 vaccine투여방법(投與方法)은 기면역율(其免疫率)과 vaccine투여(投與)로 인(因)한 손실(損失)을 좌우(左右)하게 되므로 중요(重要)한 연구과제(硏究課題)임을 인정(認定)하고 급수법(給水法)을 채택(採擇)하여 일정량(一定量)의 vaccine을 투여(投與)한후(後) 면역항체(免疫抗體)의 출현(出現)을 혈구응집조지항체(血球凝集阻止抗體)와 강독방어능력(强毒防禦能力)을 관찰(觀察)하여 구체적방법(具體的方法)을 검토(檢討)하려 하였다. 먼저 생독(生毒)vaccine으로 사용(使用)한 Lasota strain과 사독(死毒)으로 사용(使用)한 서울주(株)를 각각 $10^{-1}$에서 $10^{-11}$까지 희석(稀釋)하여 9일란(日卵)의 Allantoic Cavity로 접종(接種)하여 60시간(時間)이 경과(經過)한 후(後) Allantoic fluia를 채취(採取)하여 비교(比較)한 결과(結果) 서울주(株)는 $10^8MLD/ml$, $10^{9.6}LD_{50}/ml$였고 Lasota strain은 $10^9MID/ml$, $10^{10.5}ID_{50}/ml$였다. Formalin-mactivated Vaccine을 만들기 위(爲)하여 서울주(株)로 감염치사(感染致死)된 계태아(鷄胎兒), 양뇨막(羊尿膜), 요수등(尿水等)의 혼합유제(混合乳劑)에 Formaldehy를 1% 가(加)하여 48시간후(時間後)에 4배(四倍)의 생리식염수(生理食鹽水)를 가(加)하고 이 혼합물(混合物) 100ml에 4% "알미늄 젤"을 20ml.의 비(比)로 가(加)하여 Inactivation Test (9일(日)에 난접종(卵接種)) 및 Sterility Test(Thioglycollate Medium에 접종(接種))를 한 결과(結果) 완전(完全)히 inactivation 되었고 무균상태(無菌狀態)임을 인정(認定)한 후(後) 사용(使用)하였다. Attenuated Vaccine을 만들기 위(爲)하여는 Lasota strain을 9일란(日卵)의 Allantaic carity로 접종(接種)하여 3일간(日間) 발육(發育)케 한 후(後) Allantoic fluid를 채취(採取)하여 Allantoic fluid 100ml.에 탈지유(脫脂乳) 4ml.의 비(比)로 가(加)하여 2.5ml.식(式) 분주(分注)한 후(後) 냉동건조(冷凍乾燥)하여 $4^{\circ}C$에 보관(保管)하였다. 오개월팔일령(五個月八日齡)의 백색(白色)레구흥 200수(首)를 100수식(首式) 2군(二群)으로 나누어 각각(各各) 사독(死毒) Vaccine (1ml.I.M.) 및 생독(生毒) Vaccine (1 : 400, 10ml 경구(經口))을 투여(投與)한 후(後) 105일간(日間) 관찰(觀察)한 결과(結果) : 1. 사독(死毒) Vaccine은 HI항체(抗體)나 감염방어작용(感染防禦作用)이 105일간(日間)의 실험기간 동안 모두 고도(高度)로 유지(維持)되었다. 2. 생독(生毒) Vaccine은 감염방어작용(感染防禦作用)은 완전(完全)히 유지(維持)되었으나 HI항체(抗體)는 75일(日)까지 고도(高度)로 유지(維持)되었으나 75일후(日後)에는 약간(若干) 저하(低下)되었다. 3. 급수(給水)에 타서 경구적(經口的)으로 투여(投與)하는 생독예방접종(生毒豫防接種)은 면역기간(免疫期間)이 사독예방접종(死毒豫防接種)에 비(比)해 약간 짧은듯 싶지만 그접종방법(接種方法)이 대단히 간단하며 시간(時間)도 짧게 걸린다.

• Pediatric Infection and Vaccine
• /
• 제5권1호
• /
• pp.67-68
• /
• 1998

• 대한수의학회지
• /
• 제51권3호
• /
• pp.193-201
• /
• 2011

An attenuated vaccine strain AVR1/08 of Korean respiratory type of infectious bronchitis virus (IBV) was developed by 89th passages of IBV D85/06 strain in chicken eggs. The AVR1/08 strain had higher virus titer at least 20 times ($10^{1.3}$) than the parent virus D85/06 by egg inoculation method. The AVR1/08 strain had a single point mutation (S to Y) at position 56 of spike protein of IBV compared to parent virus IBV D85/06 strain. The mutation was observed consistently at viruses after 47th passage in chicken eggs. The AVR1/08 strain showed no virulence even after 6 passages in chickens and all chickens inoculated induced anti-IBV antibody 14 days after vaccination. The AVR1/08 strain had broad protective efficacy against QX type Korean nephropathogenic virus (Q43/06 strain), KM91 type Korean nephropathogenic virus (KM91 strain) and Korean respiratory virus (D85/06 strain). In contrast, Massachusetts (Mass) type attenuated vaccine strain H120 showed protection of 37.5 to 50% against these three viruses. Our results indicate that the AVR1/08 strain has potential as an attenuated vaccine effective in controlling IBVs circulating in Korea.

• Pediatric Infection and Vaccine
• /
• 제16권2호
• /
• pp.183-190
• /
• 2009

목 적: 본 연구에서는 일본뇌염 백신의 종류별 이상반응 발생실태를 조사하여 일본뇌염 백신의 안전성에 대한 평가를 통해 향후 일본뇌염 국가예방접종사업의 효율화를 위한 토대를 제공하고자 하였다. 방 법: 2006년 8월부터 2007년 2월까지 본 연구에 협력하기로 한 일개 대도시 지역의 보건소 4개소와 소아과 의원 9개소에서 실시되었다. 총 658명의 어린이를 대상으로 이상반응 평가가 완료되었다. 이들 어린이들을 대상으로 예방접종 당일부터 4일후까지 발적, 동통, 발열, 두통 등 상대적으로 흔한이상반응의 발생빈도 등을 전향적으로 추적 관찰하였다. 결과: 대상 소아의 평균 연령은 사백신이 1.4세(1-8.5), 생백신이 1.7세(1-8.3)였다. 그 중 보건소에서 사백신을 접종받았던 어린이는 425명(64.6%)이었으며 소아과 의원에서 생백신을 접종받은 경우는 233명(35.4%)이었다. 사백신의 경우 전체 접종 어린이 중 3.3%인 14명이 한 가지 이상의 국소 이상 반응이 나타났으며, 생백신 접종 어린이들의 2.6%가 한 가지이상의 국소 이상반응을 호소하였다. 이러한 차이는 통계적으로 유의한 수준은 아니었다(P =.607). 발열 등의 전신반응의 경우 사백신과 생백신 접종 어린이들의 각각 5.2%와 8.2%에서 나타났으나 역시 유의한 수준의 차이는 아니었다(P =.131). 사백신 접종 어린이들에서는 접종당일 발적이 4명(0.9%), 종창이 2명(0.7%), 동통이 7명(1.7%), 발열이 2명(0.5%) 나타났다. 반면 생백신 접종 어린이들의 경우 각각 4명(1.8%), 2명 (0.9%), 0명(0.0%), 6명(2.6%)에서 해당 증상을 호소하였다. 발열의 경우 통계적으로 유의하게 생백신 접종 어린이들에서 빈번하였다(P=.026). 발적, 종창, 동통, 발열 중 한 가지 이상 나타난 어린이들의 백분율은 사백신과 생백신 접종자들의 각각 3.3%와 5.2%였으며, 이는 유의한 수준의 차이는 아니었다(P =.243). 접종 1, 2, 3, 4일 후 주요 국소 및 전신 이상반응 발생빈도는 사백신과 생백신에서 유의한 차이를 보이지는 않았다. 이상반응의 세부 항목 중에서는 설사 증상만이 생백신접종 어린이들에서 유의하게 많이 나타났다(P =.044). 결 론 : 본 연구에서는 일본뇌염백신의 이상반응 발생률이 이전의 보고보다 낮았고, 접종 당일 사백신 접종자들에 비해 생백신 접종자들에서 발열이 빈번하게 관찰되었다. 그 외 사백신과 생백신의 이상반응 발생에 뚜렷한 차이가 없었다. 그러나 사백신의 경우 향후 더 많은 수의 인구 표본을 대상으로 안전성에 대한 전향적 연구가 필요하며, 생백신의 경우 안전성에 대한 객관적 경험이 더 축적되어야 할 것으로 생각된다. 아울러 가장 문제가 되고 있는 중증이상반응의 발생을 확인하기 위해서는 대규모 표본을 대상으로 지속적인 감시활동이 필요할 것으로 사료된다.